TrialsgrambetaRCTs are beautiful

TIMIC

2009

Tailored IMmunosuppression in virus-negative Inflammatory Cardiomyopathy

In 85 patients with biopsy-proven virus-negative inflammatory cardiomyopathy and heart failure refractory to conventional therapy, 6 months of prednisone plus azathioprine improved left ventricular ejection fraction at 6 months compared with placebo.

Result

Improvement in left ventricular function at 6 months
Absolute difference
24.3 points
NNT
5

Absolute difference and NNT are derived from the event rates.

Also reported: 88 % of treated patients improved versus none on placebo.

Original publication
Subtopic
Myocarditis
Design
Double-blind, placebo-controlled RCT with baseline and 6-month endomyocardial biopsy
Relevance
Supporting: context rather than must-know.
Source
Frustaci A, Russo MA, Chimenti C. Eur Heart J. 2009;30(16):1995-2002.doi 10.1093/eurheartj/ehp249

Discussion & critique

Single-centre, small, with an echocardiographic surrogate endpoint and no hard outcomes, and the strategy only works where endomyocardial biopsy with viral PCR is routine. It is the only randomised trial showing that immunosuppression reverses virus-negative inflammatory cardiomyopathy and is the direct basis for the biopsy-guided pathway.